nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—Feeling cold—Hydrochlorothiazide—nephrolithiasis	0.0795	0.111	CcSEcCtD
Nadolol—Atrioventricular block complete—Hydrochlorothiazide—nephrolithiasis	0.065	0.0905	CcSEcCtD
Nadolol—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.0405	0.0564	CcSEcCtD
Nadolol—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0358	0.0498	CcSEcCtD
Nadolol—ADRB1—Endothelin Pathways—ADCY10—nephrolithiasis	0.0313	0.111	CbGpPWpGaD
Nadolol—ADRB3—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0219	0.0779	CbGpPWpGaD
Nadolol—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.0202	0.0281	CcSEcCtD
Nadolol—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.0191	0.0265	CcSEcCtD
Nadolol—ADRB3—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0184	0.0654	CbGpPWpGaD
Nadolol—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0181	0.0252	CcSEcCtD
Nadolol—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0178	0.0247	CcSEcCtD
Nadolol—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.0174	0.0242	CcSEcCtD
Nadolol—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.0164	0.0228	CcSEcCtD
Nadolol—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0162	0.0226	CcSEcCtD
Nadolol—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0217	CcSEcCtD
Nadolol—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0151	0.021	CcSEcCtD
Nadolol—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0203	CcSEcCtD
Nadolol—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.0144	0.02	CcSEcCtD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0134	0.0477	CbGpPWpGaD
Nadolol—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0131	0.0183	CcSEcCtD
Nadolol—ADRB1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.013	0.0462	CbGpPWpGaD
Nadolol—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.013	0.018	CcSEcCtD
Nadolol—ADRB2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0127	0.0452	CbGpPWpGaD
Nadolol—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0124	0.0172	CcSEcCtD
Nadolol—Sweating—Hydrochlorothiazide—nephrolithiasis	0.0122	0.017	CcSEcCtD
Nadolol—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0165	CcSEcCtD
Nadolol—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0116	0.0162	CcSEcCtD
Nadolol—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.011	0.0153	CcSEcCtD
Nadolol—ADRB1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0109	0.0388	CbGpPWpGaD
Nadolol—ADRB2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0107	0.038	CbGpPWpGaD
Nadolol—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0148	CcSEcCtD
Nadolol—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.0101	0.014	CcSEcCtD
Nadolol—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00979	0.0136	CcSEcCtD
Nadolol—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00936	0.013	CcSEcCtD
Nadolol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00891	0.0124	CcSEcCtD
Nadolol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00873	0.0121	CcSEcCtD
Nadolol—Cough—Hydrochlorothiazide—nephrolithiasis	0.00867	0.0121	CcSEcCtD
Nadolol—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00846	0.0118	CcSEcCtD
Nadolol—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00827	0.0115	CcSEcCtD
Nadolol—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00811	0.0113	CcSEcCtD
Nadolol—Shock—Hydrochlorothiazide—nephrolithiasis	0.00798	0.0111	CcSEcCtD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00796	0.0283	CbGpPWpGaD
Nadolol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00784	0.0109	CcSEcCtD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00779	0.0277	CbGpPWpGaD
Nadolol—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00773	0.0107	CcSEcCtD
Nadolol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00758	0.0105	CcSEcCtD
Nadolol—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00733	0.0102	CcSEcCtD
Nadolol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00728	0.0101	CcSEcCtD
Nadolol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00723	0.0101	CcSEcCtD
Nadolol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00714	0.00993	CcSEcCtD
Nadolol—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00705	0.0098	CcSEcCtD
Nadolol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00699	0.00972	CcSEcCtD
Nadolol—ADRB3—G alpha (s) signalling events—PTH—nephrolithiasis	0.00694	0.0247	CbGpPWpGaD
Nadolol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00693	0.00964	CcSEcCtD
Nadolol—Pain—Hydrochlorothiazide—nephrolithiasis	0.00693	0.00964	CcSEcCtD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00655	0.0233	CbGpPWpGaD
Nadolol—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00641	0.00891	CcSEcCtD
Nadolol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00582	0.00809	CcSEcCtD
Nadolol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00574	0.00798	CcSEcCtD
Nadolol—ADRB2—GPCRs, Other—CHRM3—nephrolithiasis	0.00564	0.0201	CbGpPWpGaD
Nadolol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00555	0.00772	CcSEcCtD
Nadolol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00536	0.00746	CcSEcCtD
Nadolol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00717	CcSEcCtD
Nadolol—Rash—Hydrochlorothiazide—nephrolithiasis	0.00511	0.00711	CcSEcCtD
Nadolol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00511	0.0071	CcSEcCtD
Nadolol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00482	0.0067	CcSEcCtD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00422	0.015	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—PTH—nephrolithiasis	0.00412	0.0147	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00403	0.0143	CbGpPWpGaD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00389	0.0138	CbGpPWpGaD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.0038	0.0135	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00362	0.0129	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—RGS14—nephrolithiasis	0.00319	0.0113	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—RGS14—nephrolithiasis	0.0029	0.0103	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CHRM3—nephrolithiasis	0.00276	0.0098	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—PTH—nephrolithiasis	0.00252	0.00897	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00251	0.00892	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00245	0.00872	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—DGKH—nephrolithiasis	0.00215	0.00766	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00215	0.00764	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.0021	0.00747	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADCY10—nephrolithiasis	0.00201	0.00716	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—DGKH—nephrolithiasis	0.00196	0.00696	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00189	0.00673	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00185	0.00659	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00178	0.00633	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00178	0.00633	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RGS14—nephrolithiasis	0.00172	0.00611	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RGS14—nephrolithiasis	0.00171	0.00609	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RGS14—nephrolithiasis	0.00168	0.00598	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00164	0.00582	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CHRM3—nephrolithiasis	0.0016	0.00569	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00158	0.00564	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00156	0.00554	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—PTH—nephrolithiasis	0.0015	0.00532	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—PTH—nephrolithiasis	0.00146	0.00521	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00145	0.00516	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00145	0.00516	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PTH—nephrolithiasis	0.00142	0.00507	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CHRM3—nephrolithiasis	0.00141	0.00503	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PTH—nephrolithiasis	0.00129	0.0046	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00128	0.00455	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—DGKH—nephrolithiasis	0.00125	0.00445	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADCY10—nephrolithiasis	0.00119	0.00425	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADCY10—nephrolithiasis	0.00117	0.00416	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—DGKH—nephrolithiasis	0.00116	0.00413	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—DGKH—nephrolithiasis	0.00116	0.00411	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00116	0.00411	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—DGKH—nephrolithiasis	0.00114	0.00404	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0011	0.00391	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0011	0.00391	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00102	0.00363	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00102	0.00363	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RGS14—nephrolithiasis	0.00102	0.00361	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RGS14—nephrolithiasis	0.000993	0.00353	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000924	0.00329	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00091	0.00324	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00091	0.00324	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000904	0.00322	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PTH—nephrolithiasis	0.000845	0.00301	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000839	0.00299	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CHRM3—nephrolithiasis	0.000835	0.00297	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PTH—nephrolithiasis	0.000827	0.00294	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000821	0.00292	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PTH—nephrolithiasis	0.000768	0.00273	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTH—nephrolithiasis	0.000764	0.00272	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PTH—nephrolithiasis	0.000751	0.00267	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000728	0.00259	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000686	0.00244	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—DGKH—nephrolithiasis	0.000686	0.00244	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000671	0.00239	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—DGKH—nephrolithiasis	0.000671	0.00239	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000631	0.00225	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000563	0.002	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CHRM3—nephrolithiasis	0.000496	0.00176	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CHRM3—nephrolithiasis	0.000485	0.00173	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APRT—nephrolithiasis	0.000478	0.0017	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000478	0.0017	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTH—nephrolithiasis	0.000453	0.00161	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTH—nephrolithiasis	0.000444	0.00158	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SPP1—nephrolithiasis	0.000384	0.00136	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000341	0.00121	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.000308	0.0011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SPP1—nephrolithiasis	0.000228	0.00081	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SPP1—nephrolithiasis	0.000223	0.000792	CbGpPWpGaD
